Home › Companies › ZURA
Zura Bio
Market cap $99.7M 96.3M shares (10-Q, Oct 27, 2026) × $1.03 close Nov 17, 2026
Most recent annual filing: 2026-03-19
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- Third indication undisclosed Ph2 startby year-end 2026Third indication undisclosed Ph2 start, by year-end 2026, routine
- Tibulizumab TibuSURE topline1H 2027Tibulizumab TibuSURE topline, 1H 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (4 active programs)
tibulizumab
ZB-106
crebankitug
ZB-168 - Undisclosed indication Phase 1 Pfizer
torudokimab
ZB-880 Discontinued (1)
- tibulizumab — Hidradenitis Suppurativa · missed primary endpoint in Phase 2
Capital (as filed)
- Cash
- $188M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$19K quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $188M cash, runway through at least the end of 2028 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Zura Bio, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-30 Watch Zura Bio Limited (ZURA) - Scientific Deep Dive for Tibulizumab and Pipeline Products Legitimately de-risked financing and a real Q4 2026 binary keep this off the Pass pile, but the entire incremental thesis rides on the unproven BAFF arm, with governance/SPAC overhang and a stock already tripled off its lows — no clear edge in owning before HS data prints.
- 2026-08-12 Watch UPDATE: Zura Bio (ZURA) - The Third Shot on Goal Gets a Name PMR naming adds a setting where both IL-17 and BAFF arms have randomized clinical support, modestly narrowing the bear case, but the differentiating BAFF contribution in HS remains unproven and Q4 2026 remains a binary with the stock more than tripled off its lows.
- 2026-11-10 Avoid UPDATE: Zura Bio (ZURA) - The Placebo Ate the Readout TibuSHIELD missed every efficacy endpoint at both doses with no dose response, Zura is exiting HS, and the remaining value rests on an mRSS endpoint graveyard with a molecule whose tissue penetration is now in question and cash earmarked for burn rather than shareholders.
- Avoid call · opened Nov 10, 2026 at $1.41 · -26.3% vs XBI -6.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (4 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Topline data are anticipated in the fourth quarter of 2026.”
matched to Tibulizumab (ZB-106) · topline data · since happened Nov 9, 2026
-
-
“Topline results are expected to be available in the fourth quarter of 2026.”
matched to Tibulizumab (ZB-106) · topline data · since happened Nov 9, 2026 -
“Topline data are anticipated in the fourth quarter of 2026.”
matched to Tibulizumab (ZB-106) · topline data · since happened Nov 9, 2026
-
-
“Topline results are expected to be available in the fourth quarter of 2026.”
matched to Tibulizumab (ZB-106) · topline data · since happened Nov 9, 2026
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (24)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Aug 11, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseZura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1→ BD updateTibuSHIELD failed across every endpoint — primary AN count miss, HiSCR50 miss, HiSCR75 miss — with placebo response rates so high the drug couldn't separate, and HS development is now discontinued. The bear case the original writeup laid out has arrived: the BAFF arm never earned its keep, and the stock has crashed ~70% today to reflect it.
- Oct 27, 2026S-3Shelf registration
- Oct 27, 2026ReleaseZura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
- Oct 27, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Oct 27, 202610-QQuarterly report
- Aug 31, 2026ReleaseZura Bio to Participate in the Cantor Global Healthcare Conference
- Aug 17, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Aug 11, 2026ReleaseZura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
- Aug 11, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jul 1, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Jun 18, 20268-KCurrent report: officer / director change, shareholder vote
- May 22, 2026DEFA14AProxy soliciting material
- May 22, 20268-KCurrent report: officer / director change
- May 7, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 30, 2026DEF 14AProxy statement
- Apr 23, 20268-KCurrent report: officer / director change
- Mar 19, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Mar 19, 202610-KAnnual report
- Mar 10, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Mar 5, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Mar 2, 2026SCHEDULE 13D/A13D amendment
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)